<style type="text/css"> .wpb_animate_when_almost_visible { opacity: 1; }</style>
  • Using technology in tumor genomics to develop precision cancer therapeutics

    Investor Relations

Press Releases

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2012 Archives

Nov 18, 2012
Renowned molecular geneticist strengthens Trovagene's scientific expertise
Nov 14, 2012
COMPANY CONTINUES TO DEVELOP PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE
Aug 28, 2012
Issuance of First US NPM1 Patent Triggers Milestone Payment
Aug 14, 2012
COMPANY CONTINUES TO EXPAND PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE
Jul 2, 2012
Study will compare detection of KRAS mutations in urine to their detection in biopsy samples
Apr 30, 2012
Internationally recognized cancer researcher and physician strengthens Trovagene's scientific expertise in cancer genetics
Apr 30, 2012
Company plans to establish comprehensive panel of assays to detect oncogene mutations in the urine of cancer patients
Apr 22, 2012
- Pharmaceutical and diagnostic sales and marketing executive will provide leadership to accelerate commercial programs -
 

email print rss
3:34
3:34
Wistia video thumbnail - Susann-Berz Patient Video- Home Page

Thanks for reporting a problem. We'll attach technical data about this session to help us figure out the issue. Which of these best describes the problem?

Any other details or context?

Cancel
message